EAM
MSLE

Empery Asset Management’s Satellos Bioscience MSLE Stock Holding History

Empery Asset Management’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$833K Sell
107,100
-123,000
-53% -$845K 0.96% 15
2026
Q1 		$1.3M Buy
+230,100
New +$2.26M 1.56% 11

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Empery Asset Management's MSLE Position: Q2 2026 in Review

Empery Asset Management reduced its Satellos Bioscience (MSLE) stake by 53% in Q2 2026, selling an estimated $845K and leaving 107,100 shares worth $833K. The position accounts for 0.96% of the portfolio, ranked #15.

Empery Asset Management first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.3M in Q1 2026. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • Empery Asset Management held 107,100 shares of Satellos Bioscience worth $833K as of Q2 2026.
  • Empery Asset Management sold 123,000 Satellos Bioscience shares in Q2 2026, an estimated $845K.
  • Satellos Bioscience made up 0.96% of Empery Asset Management's portfolio in Q2 2026, its #15 holding.
  • Empery Asset Management first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Empery Asset Management's Satellos Bioscience position peaked at $1.3M in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on Empery Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.